Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The primary objective was to determine superiority of dulaglutide 1.5 mg versus placebo in HbA1c change at 26 weeks. RESEARCH DESIGN AND METHODS: This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5 mg, dulaglutide 0.75 mg, exenatide 10 μg, or placebo (placebo-controlled period: 26 weeks). Patients were treated with metformin (1,500–3,000 mg) and pioglitazone (30–45 mg). Mean baseline HbA1c was 8.1% (65 mmol/mol). RESULTS: Least squares mean ± SE HbA1c change from baseline to the primary end point was −1.51 ± 0.06% (−16.5 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, −1.30 ± 0.06% (−14.2 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, −0.99 ± 0.06% (−10.8 ± 0.7 mmol/mol) for exenatide, and −0.46 ± 0.08% (−5.0 ± 0.9 mmol/mol) for placebo. Both dulaglutide doses were superior to placebo at 26 weeks (both adjusted one-sided P < 0.001) and exenatide at 26 and 52 weeks (both adjusted one-sided P < 0.001). Greater percentages of patients reached HbA1c targets with dulaglutide 1.5 mg and 0.75 mg than with placebo and exenatide (all P < 0.001). At 26 and 52 weeks, total hypoglycemia incidence was lower in patients receiving dulaglutide 1.5 mg than in those receiving exenatide; no dulaglutide-treated patients reported severe hypoglycemia. The most common gastrointestinal adverse events for dulaglutide were nausea, vomiting, and diarrhea. Events were mostly mild to moderate and transient. CONCLUSIONS: Both once-weekly dulaglutide doses demonstrated superior glycemic control versus placebo and exenatide with an acceptable tolerability and safety profile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another analog of human of GLP-1, but in once weekly administration, was similarly found to be superior to exenatide twice daily in reducing HbA1C, −1.51% vs. −0.99%.18”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [18]
In the citing paper
“The most common adverse events (AEs) reported with GLP-1RAs were gastrointestinal disorders, such as nausea, diarrhea, vomiting, and abdominal pain, etc (7–9).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [8]
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“American Indian 40 (14) 37 (13) 38 (14) 20 (14)”
ResultBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
“In the presence of HSA, TZP right-shifts 81-fold (n = 5), while the potency of GLP-1(7-36) is unaltered (n = 24).”
InfluentialDungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Self-citationHuman cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Dumont, J., Euwart, D., Mei, B., Estes, S., & Kshirsagar, R. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1084266 · Cited by 483
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416
Gilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282
Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268
Ludvik, B., Frías, J. P., Tinahones, F. J., Wainstein, J., Jiang, H., Robertson, K. E., García-Pérez, L.-E., Woodward, D. B., & Milicevic, Z. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30023-8 · Cited by 266
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
Blonde, L., Jendle, J., Gross, J., Woo, V., Jiang, H., Fahrbach, J. L., & Milicevic, Z. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60936-9 · Cited by 227
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
Brown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Anti-diabetic drugs and weight loss in patients with type 2 diabetes
Lazzaroni, E., Ben Nasr, M., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105782 · Cited by 182
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Self-citationCornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., & Milicevic, Z. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12479 · Cited by 149
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
del Olmo-Garcia, M. I., & Merino-Torres, J. F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4020492 · Cited by 138
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
Trujillo, J. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 130
Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4289-0 · Cited by 117
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Maloney, A., Rosenstock, J., & Fonseca, V. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1307 · Cited by 115
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114
Geiser, J. S., Heathman, M. A., Cui, X., Martin, J. A., Loghin, C., Chien, J. Y., & de la Peña, A. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0338-3 · Cited by 126
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Exenatide: pharmacokinetics, clinical use, and future directions
Knop, F. K., Brønden, A., & Vilsbøll, T. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1282463 · Cited by 105
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
Tran, K., Park, Y. I., Pandya, S., Muliyil, N. J., Jensen, B. D., Huynh, K., & Nguyen, Q. P. H. (2017) · PubMed · Cited by 124
Dungan, K. M., Weitgasser, R., Perez Manghi, F., Pintilei, E., Fahrbach, J. L., Jiang, H. H., Shell, J., & Robertson, K. E. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12634 · Cited by 99
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
Gallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13086 · Cited by 98
Miyagawa, J., Odawara, M., Takamura, T., Iwamoto, N., Takita, Y., & Imaoka, T. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12534 · Cited by 96
Burcelin, R., & Gourdy, P. (2017) · Obesity Reviews · doi:10.1111/obr.12465 · Cited by 94
GLP‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
Trujillo, J. M., & Nuffer, W. (2014) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1507 · Cited by 95
Effects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
“Gastrointestinal symptoms are common side effects of GLP-1 agonists (37–40) and might have affected alcohol intake.”
BackgroundGLP-1 Agonists and Blood Pressure: A Review of the Evidence
Goud, A., Zhong, J., Peters, M. C., Brook, R. D., & Rajagopalan, S. (2016) · Current Hypertension Reports · doi:10.1007/s11906-015-0621-6 · Cited by 104
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Mody, R., Huang, Q., Yu, M., Zhao, R., Patel, H., Grabner, M., & Landó, L. F. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13603 · Cited by 93
Zaccardi, F., Htike, Z. Z., Webb, D. R., Khunti, K., & Davies, M. J. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1432 · Cited by 91
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Vega, E. T., Linz, B., Eggertsen, C. H. E., Mulvey, J., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae120 · Cited by 84
Cusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13697 · Cited by 89
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87
Yang, Y., He, L., Han, S., Yang, N., Liu, Y., Wang, X., Li, Z., Ping, F., Xu, L., Li, W., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70063 · Cited by 74
Cheang, J. Y., & Moyle, P. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201700781 · Cited by 82
Gan, S., Dawed, A. Y., Donnelly, L. A., Nair, A. T. N., Palmer, C. N. A., Mohan, V., & Pearson, E. R. (2020) · Diabetes Care · doi:10.2337/dc19-2419 · Cited by 83
Araki, E., Inagaki, N., Tanizawa, Y., Oura, T., Takeuchi, M., & Imaoka, T. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12540 · Cited by 82
Horowitz, M., Aroda, V. R., Han, J., Hardy, E., & Rayner, C. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12872 · Cited by 79
Lee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 79
Role of glucagon-like peptide 1 receptor agonists in management of obesity
Isaacs, D., Prasad-Reddy, L., & Srivastava, S. B. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150990 · Cited by 75
Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74
Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M. C., Mallory, J., & Home, P. (2020) · Diabetes Care · doi:10.2337/dc19-2316 · Cited by 73
Ayoub, M., Chela, H. K., Amin, N. A., Hunter, R., Anwar, J., Tahan, V., & Daglilar, E. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030944 · Cited by 94
Adetunji, O., Kalra, S., Baruah, M., Sahay, R., Unnikrishnan, A., & Uppal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176351 · Cited by 71
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
Tuttolomondo, A., Cirrincione, A., Casuccio, A., Del Cuore, A., Daidone, M., Di Chiara, T., Di Raimondo, D., Corte, V. D., Maida, C., Simonetta, I., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01183-5 · Cited by 69
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
Dulaglutide: First Global Approval
Sanford, M. (2014) · Drugs · doi:10.1007/s40265-014-0320-7 · Cited by 75
Shestakova, M. V., & Александровна, Ю. Е. (2015) · Diabetes Mellitus · doi:10.14341/dm20151s1-112 · Cited by 71
Ninčević, V., Kolarić, T. O., Roguljić, H., Kizivat, T., Smolić, M., & Bilić-Čurčić, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235831 · Cited by 77
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 79
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 74
The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Hayes, M. R., Borner, T., & De Jonghe, B. C. (2021) · Diabetes · doi:10.2337/dbi21-0004 · Cited by 64
Ji, L., Jiang, H., An, P., Deng, H., Liu, M., Li, L., Feng, L., Song, B., Han-Zhang, H., Ma, Q., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101088 · Cited by 63
Ferdinand, K. C., Botros, F. T., Atisso, C. M., & Sager, P. T. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0355-z · Cited by 61
Self-citationRen, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Odawara, M., Miyagawa, J., Iwamoto, N., Takita, Y., Imaoka, T., & Takamura, T. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12602 · Cited by 56
Peptibodies: An elegant solution for a long‐standing problem
Cavaco, M., Castanho, M. A. R. B., & Neves, V. (2018) · Peptide Science · doi:10.1002/bip.23095 · Cited by 57
Karagiannis, T., Liakos, A., Bekiari, E., Athanasiadou, E., Paschos, P., Vasilakou, D., Mainou, M., Rika, M., Boura, P., Matthews, D. R., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12541 · Cited by 56
Dalsgaard, N. B., Vilsbøll, T., & Knop, F. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13128 · Cited by 54
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Xu, D., Nair, A., Sigston, C., Ho, C., Li, J., Yang, D., Liao, X., Chen, W., Kuang, M., Li, Y., et al. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/6820377 · Cited by 50
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Kang, Y. M., & Jung, C. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.258 · Cited by 51
Ebrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
Wang, W., Nevárez, L., Filippova, E., Song, K. H., Tao, B., Gu, L., Wang, F., Li, P., & Yang, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13506 · Cited by 51
Dulaglutide: A Review in Type 2 Diabetes
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01260-9 · Cited by 56
Transdermal Drug Delivery Systems and Their Use in Obesity Treatment
Li, Z., Fang, X., & Yu, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312754 · Cited by 59
Dulaglutide: The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes
Thompson, A. M., & Trujillo, J. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014564180 · Cited by 51
Zhang, Y. L., Zhou, C., Li, X. F., Yang, M. N., Tao, L., Zheng, X. Y., & Jia, Y. S. (2019) · Obesity Science & Practice · doi:10.1002/osp4.342 · Cited by 49
“This phenomenon of β-cell rest was also observed in previous studies of GLP-1 (7-36) and exendin-4 in the postprandial state (23–25).”
BackgroundResultXie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 57
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S. H., & Rendell, M. S. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 46
R. Drab, S. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666151223093841 · Cited by 47
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
Takase, T., Nakamura, A., Yamamoto, C., Nomoto, H., Miya, A., Dannoura, M., Cho, K. Y., Kurihara, Y., Manda, N., Aoki, S., et al. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12906 · Cited by 47
Frias, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartaskova, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Milicevic, Z. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13764 · Cited by 46
Metadata
- Authors
- Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M.
- Affiliations
- Redwood Clinic, Spokane, WA
- Texas Diabetes & Endocrinology (US)
- University of Hawaiʻi at Mānoa (US)
- American Telemedicine Center of Puerto Rico, San Juan, PR
- University Hospital Autonomous University of Nuevo León, Monterrey, Mexico
- Eli Lilly (United States) (US)
- Corresponding author
- Lakshmanan, Mark
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-07-12
- Volume
- 37
- Issue
- 8
- Pages
- 2159-2167
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2104252114
- Cited by
- 396
- References
- 24
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 26 · 2023: 27 · 2022: 15 · 2021: 25 · 2020: 31 · 2019: 31 · 2018: 34 · 2017: 38 · 2016: 47 · 2015: 44 · 2014: 10
- FWCI
- 37.26
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-10-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- dulaglutide, exenatide, type 2 diabetes, GLP-1 receptor agonists, pioglitazone, metformin, HbA1c, glycemic control, hypoglycemia, drug safety, combination therapy, dose comparison, HbA1c targets, weight gain, adverse events
- MeSH terms
- Pioglitazone, Exenatide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Peptides, Recombinant Fusion Proteins, Venoms, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.